BACKGROUND: Parathyroid hormone (PTH) is a novel promising biomarker that can predict hospitalization, functional status and mortality in patients who suffered heart failure with preserved ejection fraction (HFpEF). OBJECTIVE: We aimed to investigate the association of serum PTH levels and measures of disease severity (NYHA functional class, NT-proBNP, CRP, EF, Troponin I) in patients with HFpEF. METHODS: A total of consecutive 58 outpatients with HFpEF and 30 controls were prospectively studied. All patients underwent laboratory tests, including NT-proBNP and PTH analyses. RESULTS: PTH, NT-proBNP, troponin I, and CRP levels were signifi cantly higher in patients with HFpEF when compared with control group (54.61 ± 31.02 vs 40.40 ± 14.22 pg/ml, p < 0.05; 126.05 ± 162.94 vs 44.57 ± 14.95 pg/ml, p < 0.01; 0.011 ± 0.013 vs 0.004 ± 0.001 ug/L, p < 0.01; 4.65 ± 4.24 vs 1.63 ± 0.97 mg/L, p < 0.01, respectively). Left atrium was found to be more enlarged in HFpEF patients (LAVI = 36 ± 18 vs 28 ± 11 ml/m², p < 0.01). Most indices of left ventricular diastolic function were more severely impaired compared to controls (p < 0.05). There was no correlation between PTH and CRP, troponin I, LVMI, LV volumes, LV diameters, E/E', age, and BMI in both groups (p = NS). There was strong positive correlation between PTH and NT-proBNP levels in all study participants (r = 0.359; p < 0.01). CONCLUSION: PTH together with other markers of heart failure may provide valuable information both in the diagnosis and staging of heart failure syndromes (Tab. 4, Fig. 1, Ref. 40) . Text in PDF www.elis.sk.
Introduction
Heart failure with preserved ejection fraction (HFpEF) is a common and increasing public health issue related with significant morbidity and mortality. HFpEF currently accounts for ≥ 50 % of the general heart failure population, and its 1-and 5-year survival rates are similar to or only slightly better than those of patients with reduced ejection fraction (HFrEF) (1) (2) (3) (4) .
T h e diagnosis of HFpEF requires the following four criteria to be fulfi lled: (i) presence of signs or (ii) symptoms of heart failure; (iii) normal or near normal systolic function (EF ≥ 50 %) and LV not dilated; and (iv) relevant structural heart disease (LV hypertrophy/ LA enlargement) and/or diastolic dysfunction (4) . Impairment in left ventricular (LV) diastolic function related with myocardial hypertrophy and fi brosis has been proposed as a key pathophysiologic mediator. Noninvasive estimation of LV fi lling pressures is a clinical requisite to make the diagnosis of diastolic dysfunction (5) .
Parathyroid hormone (PTH) which is responsible for calcium homeostasis is an independent predictor of severity, prognosis and need for hospitalization in patients with HFrEF (6, 7) . Several factors including hypovitaminosis D, aldosteronism, chronic use of furosemide and impaired renal function have been shown to contribute to the appearance of secondary hyperparathyroidism in HF patients (8) (Fig. 1) .
PTH was demonstrated to be a pro-hypertrophic factor by increasing protein synthesis in vitro. Cardiomyocytes were reported to be targets of PTH (9, 10) . A signifi cant association was demonstrated between LV mass and PTH level both in healthy population (11) and patients with different diseases (12, 13) .
We aimed to investigate the association of serum PTH levels and measures of disease severity (NYHA functional class, NT-proBNP, CRP, EF, troponin I) in patients with HFpEF. Also we searched for the relationship between PTH levels and diastolic parameters in patients with preserved systolic function.
Method
Following the obtaining of informed consent for the study, all patients underwent a comprehensive echocardiographic examination. We prospectively enrolled 60 patients who met the diagnostic clinical heart failure criteria and 30 controls. Demographic data including age, gender, body mass index (BMI), body surface area (BSA) and comprehensive clinical data including history of hypertension, diabetes mellitus, dyslipidemia, history of smoking, coronary artery disease, peripheral arterial disease, history of prior myocardial infarction and coronary artery bypass surgery were collected. Systolic and diastolic blood pressures were measured at the time of echocardiographic exam.
Exclusion criteria for the study were chronic renal failure (creatinine clearance < 90 ml/min/1.7 m 2 ), long-term alcoholism, pancreatitis, primary hyperparathyroidism, malignancy, liver disease and spironolacton use.
All patients had signs and symptoms of heart failure, and a normal or near normal ejection fraction (LVEF ≥ 50 %), non-dilated LV cavity and associated structural heart disease and/or left atrial enlargement and/or LV diastolic dysfunction as stated in the ESC guidelines for heart failure (4) . The study participants were divided into 4 functional groups based on NYHA class. Anemia was defi ned as hemoglobin level < 13 g/dl in men and < 12 g/dl in women in accordance with World Health Organization criteria. Hypertension was defi ned as blood pressure > 140/90 mmHg on > 2 occasions during offi ce measurement or on antihypertensive drug.
Comprehensive laboratory tests, including measurements of NT-proBNP, PTH and troponin I levels were performed. NT-proBNP levels were measured using an enzyme immunoassay technique. The established normal range for NT-proBNP assay was: 0-125 pg/ml for ages 2-74; 0-450 pg/ml for ages > 75. The established normal range for PTH and troponin I were 15-65 pg/ ml and 0-0.014 ug/L, respectively. PTH level was measured by using Cobas e 601(Roche Diagnostics, Germany) analyzer with electrochemiluminescence immunoassay (ECLIA) method. CRP levels were calculated (normal range: 0-5 mg/L) by using Cobas e 601 (Roche Diagnostics, Germany) analyzer with immunoturbidimetric method.
Echocardiographic assessment
All participants underwent a complete transthoracic echocardiography according to the American Society of Echocardiography guidelines (14) by one operator, who was blinded to the clinical and laboratory results of the study group. Transthoracic echocardiographic studies were carried out with the patient in the left lateral position using a GE Vivid 7 system (GE, Horten, Norway) with a 3.5-MHz transducer. All data were transferred to a workstation for further offl ine analysis (EchoPAC-PC v7.1,2; GE Vingmed Ultrasound AS, Horten, Nor-way). LV internal dimensions (enddiastolic LV diameter and end-systolic LV diameter) and wall thickness of the ventricular septum and posterior wall were measured from two-dimensional (2D-guided) M-mode echocardiographic tracings obtained at the mid-chordal level of the parasternal long axis. LV end-diastolic and end-systolic volumes and EF were measured in apical two-chamber (2C) and four-chamber views. LA volume (ml/ m2) was measured using the biplane area-length method and normalized for body surface area. The transmitral fl ow velocity was obtained from apical 4C view with the pulsed-wave Doppler method. After measuring the peak early (E) and late (A) diastolic velocities and deceleration time (DT), the ratio of early to
Fig. 1. Relationship between parathyroid hormone and NT-proBNP in patients with HFpEF and control group.
Patients with HFpEF (n = 58) (mean±SD) 
Results
Baseline characteristic and clinical data of study participants were demonstrated in Table 1 . Age of patients with HFpEF and control group was comparable (62 ± 9 vs 61 ± 7, respectively; p: NS). Body mass indices of patients with HFpEF were signifi cantly higher compared to control group (p < 0. 01). Similarly, both systolic and diastolic blood pressures in patients with HFpEF were detected to be higher than those in control group (p < 0.05).
PTH 
Tab. 3. Two-dimensional and Doppler echocardiographic fi ndings of patients with heart failure with preserved ejection fraction vs control group
LDL levels were signifi cantly higher in patients with HFpEF than those in control group (p < 0.05).
In comparison to control group, left atrium was found to be more enlarged in HFpEF patients (p < 0.05) (Tab. 3). Velocity of early diastolic fi lling (E) was found to be signifi cantly lower in patients with HFpEF (p < 0.01). In contrast, velocity of late diastolic fi lling (A) was signifi cantly higher in patients with HFpEF (p < 0.01). DT of patients with HFpEF was found to be prolonged compared to control group (p < 0.01). IVRT was shorter in control group in a borderline signifi cance compared to patients with HFpEF.
E/E' were detected higher in patients with HFpEF (p < 0.01). EF and size of LV were similar in both groups. But LV wall thickness, RWT, and LV mass index were signifi cantly higher in patients with HFpEF compared to control group.
There was no correlation between PTH and CRP, troponin I, LVMI, LV volumes, LV diameters, E/E', age, and BMI in both groups (p = NS) (Tab. 4). In contrast, there was a statistically signifi cant and strong positive correlation between PTH and NT-proBNP levels in all study participants (r = 0.359; p < 0.01). Also, there was a statistically signifi cant and positive correlation between PTH and NT-proBNP levels in patients with HFpEF (r = 0.322; p < 0.05).
There were no differences in PTH measurements according to the presence of CAD in all participants (p > 0.05). PTH levels were detected in signifi cantly higher levels in hypertensive HFpEF patients compared to non-hypertensive HFpEF patients (p < 0.05). There was no signifi cant difference in PTH levels by the presence of CAD in HFpEF cases (p > 0.05).
Discussion
PTH has been linked to HF with levels of PTH being predictive for hospitalization in patients with HF (6) . PTH promotes intracellular calcium overloading including the mitochondria, which causes destruction of these organelles, ending with cardiomyocyte necrosis and, hence, leakage of troponins.
Secondary hyperparathyroidism (HPTH) was associated with increased mortality and risk of hospitalization (17, 18) . There are various mechanisms through which high levels of PTH could have harmful effects on the cardiovascular system. In vitro studies have found PTH to have chronotropic (19) and inotropic effects on cardiac muscle (20) . Higher PTH may promote specifi c vascular pathology such as endothelial dysfunction and atherosclerosis (21, 22) that leads to cardiac ischemia and consequent HF. Both experimental and clinical data suggest that PTH has direct detrimental myocardial effects that could lead to increased myocardial susceptibility for cardiac ischemia or increased risk for HF of non-ischemic origin. For instance, myocytes have been shown to be target cells for PTH and higher PTH may induce myocyte hypertrophy, fi brosis, and LVH (23) (24) (25) (26) . HPTH has been linked with arterial stiffness and hypertension (19, 26) . PTH exerts a trophic effect on cardiomyocytes with an increase in total cellular mass, while higher serum PTH concentrations are associated with LVH in the general population (10, 27, 28) . Increased PTH level is important as a marker of prognosis. It was found to be related with cardiovascular death in elderly Swedish people (29) . High serum PTH levels were strongly associated with advanced HF (6) . This association has been explained by the fact that secondary HPTH may contribute to the systemic illness that accompanies advanced HF (30) .
Although EF seems to be normal in the patients with HFpEF, pathologic changes in myocardium especially hypertrophy, necrosis and scarring are important. Many previous studies have found that NT-proBNP levels in HFpEF patients are less elevated than in patients with heart failure with reduced EF (31) and that levels tend to be less elevated in patients with chronic heart failure than in those with acute heart failure (30) . In contrast to our fi ndings, several recent studies have also demonstrated that a great proportion of HFpEF patients have normal NT-proBNP levels (33) (34) (35) .
There is a considerable number of studies showing that E/e' correlates well with LV fi lling pressure and it is regarded as one of the most important non-invasive parameters for estimation of LV fi lling pressure (36, 37). Moreover, E/e' has been shown to be independently predictive of cardiovascular events (38, 39) .
In our patient group, PTH and NT-proBNP levels were significantly higher than those of controls. The more severe the disease; the more elevated NT-proBNP levels were noted. PHT was found to be related with NT-proBNP levels. Moreover, NT-proBNP is correlated with PTH in our study.
We suggest that PTH could provide complementary information about the severity of HFpEF. PTH together with other markers like troponin and NT-proBNP give valuable data both in the diagnosis and staging of heart failure syndromes.
Conclusion
We are supposing that our work will be a guide for subsequent studies searching for PTH and related responsible mechanisms causing HFpEF. Our study will also contribute to the prevention of myocardial damage as a primary underlying mechanism of heart failure and more effective treatment of HFpEF, which is an area with limited proven data.
Limitations
The limitations of the present study include its relatively small sample size and the cross-sectional design. In addition, we did not measure serum ionized calcium or magnesium, which are important determinants of PTH secretion. The use of a comprehensive clinical diagnosis as diagnostic standard for HFpEF patients, without an invasive measurement to confi rm LV diastolic dysfunction is another drawback of our study. Additionally, LVEF was measured by the biplane Simpson's method in the present study, which might be a poor tool for detecting longitudinal systolic dysfunction. However, previous authors have demonstrated depressed longitudinal strain in HFpEF (40) .
